Lupin shares 0.08% as Sensex falls

 21 Nov 2024 10:35 AM

On the technical charts, the RSI of the stock stood at 37.11.

Share price of Lupin as Nifty

 19 Nov 2024 01:42 PM

A total of 8,636 shares changed hands on the counter till 01:42PM (IST).

Lupin shares 0.73% as Nifty drops

 18 Nov 2024 11:31 AM

A total of 7,998 shares changed hands on the counter till 11:29AM (IST).

Lupin shares 2.31% as Nifty drops

 13 Nov 2024 12:52 PM

A total of 8,814 shares changed hands on the counter till 12:51PM (IST).

Lupin stock price 0.4 per cent as Sensex

 08 Nov 2024 11:02 AM

As of 30-Sep-2024, promoters held 46.68 per cent stake in the company, while FIIs held 21.5 per cent and domestic institutional investors had 16.89 per cent.

LUPIN: US SALES OF USD 220M VS EST USD 232M

 08 Nov 2024 08:59 AM

LUPIN: US SALES OF USD 220M VS EST USD 232M

Tata Consumer Products, Lupin among 10 stocks that LIC sold in Q2

 08 Nov 2024 08:15 AM

LIC reduced its stake in key stocks, including Voltas, Lupin, Hero MotoCorp, and Tata Power, lowering its overall share in NSE-listed companies to 7.34% by September 2024.

Lupin Q2 Results: Rs 853 crore profit beats St view on strong demand for generic drugs

 07 Nov 2024 07:04 PM

Lupin exceeded profit expectations in the second quarter, reporting a 74% surge in profits, reaching ₹8.53 billion. This growth was fueled by robust demand for their respiratory and diabetes medications. Overall revenue also saw an 11.3% increase, reaching ₹54.97 billion.

Lupin Q2 Results: Net profit soars 74% YoY to Rs 853 crore on strong demand for generic drugs

 07 Nov 2024 07:04 PM

Lupin exceeded profit expectations in the second quarter, reporting a 74% surge in profits, reaching ₹8.53 billion. This growth was fueled by robust demand for their respiratory and diabetes medications. Overall revenue also saw an 11.3% increase, reaching ₹54.97 billion.

LUPIN: Q2 EBITDA 13.4B RUPEES VS 9.2B (YOY); EST 12.2B || Q2 EBITDA MARGIN 23.63% VS 18.21% (YOY); EST 22%

 07 Nov 2024 06:47 PM

LUPIN: Q2 EBITDA 13.4B RUPEES VS 9.2B (YOY); EST 12.2B || Q2 EBITDA MARGIN 23.63% VS 18.21% (YOY); EST 22%